Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 2
1949 1
1951 1
1953 1
1956 1
1958 1
1959 1
1961 1
1964 2
1965 14
1966 42
1967 57
1968 96
1969 79
1970 103
1971 80
1972 91
1973 108
1974 134
1975 83
1976 87
1977 106
1978 90
1979 95
1980 100
1981 95
1982 122
1983 96
1984 123
1985 125
1986 142
1987 155
1988 158
1989 214
1990 251
1991 292
1992 260
1993 345
1994 304
1995 279
1996 284
1997 244
1998 218
1999 202
2000 209
2001 193
2002 207
2003 200
2004 208
2005 226
2006 245
2007 224
2008 265
2009 273
2010 290
2011 303
2012 313
2013 318
2014 359
2015 335
2016 342
2017 344
2018 359
2019 349
2020 271
Text availability
Article attribute
Article type
Publication date

Search Results

10,517 results
Results by year
Filters applied: . Clear all
Page 1
Allopurinol and kidney function: An update.
Stamp LK, Chapman PT, Palmer SC. Stamp LK, et al. Joint Bone Spine. 2016 Jan;83(1):19-24. doi: 10.1016/j.jbspin.2015.03.013. Epub 2015 Oct 6. Joint Bone Spine. 2016. PMID: 26453097 Review.
Allopurinol is the most commonly used urate lowering therapy in the management of gout. Despite the fact that it has been available for over 40 years there is ongoing debate about optimal allopurinol dosing in gout patients with chronic kidney disease. ...This revie
Allopurinol is the most commonly used urate lowering therapy in the management of gout. Despite the fact that it has been available f
Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment.
Vargas-Santos AB, Peloquin CE, Zhang Y, Neogi T. Vargas-Santos AB, et al. JAMA Intern Med. 2018 Nov 1;178(11):1526-1533. doi: 10.1001/jamainternmed.2018.4463. JAMA Intern Med. 2018. PMID: 30304329 Free PMC article.
IMPORTANCE: Clinicians are often cautious about use of allopurinol in patients with gout when renal function declines. OBJECTIVE: To assess the association of allopurinol use in gout with the risk of developing chronic kidney disease stage 3 or higher. ...Allopur
IMPORTANCE: Clinicians are often cautious about use of allopurinol in patients with gout when renal function declines. OBJECTIVE: To …
Allopurinol: insights from studies of dose-response relationships.
Day RO, Kannangara DR, Stocker SL, Carland JE, Williams KM, Graham GG. Day RO, et al. Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):449-462. doi: 10.1080/17425255.2017.1269745. Epub 2016 Dec 20. Expert Opin Drug Metab Toxicol. 2017. PMID: 27927043 Review.
Significant aspects discussed are the importance of adherence to allopurinol therapy, allopurinol hypersensitivity reactions and insights into hyperuricemia. ...Allopurinol is generally well tolerated and screening for genetic factors predictive of allopur
Significant aspects discussed are the importance of adherence to allopurinol therapy, allopurinol hypersensitivity reactions a …
Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score-matched landmark analysis.
Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Kuo CF, et al. Rheumatology (Oxford). 2015 Dec;54(12):2145-50. doi: 10.1093/rheumatology/kev246. Epub 2015 Jul 12. Rheumatology (Oxford). 2015. PMID: 26170376
RESULTS: Of 23 332 incident gout patients identified, the propensity score-matched cohorts contained 1016 patients exposed to allopurinol on the date 1 year from diagnosis (landmark date) and 1016 allopurinol non-users. Over a median follow-up period of 10 years aft …
RESULTS: Of 23 332 incident gout patients identified, the propensity score-matched cohorts contained 1016 patients exposed to allopurinol
Allopurinol treatment adversely impacts left ventricular mass regression in patients with well-controlled hypertension.
Gingles CR, Symon R, Gandy SJ, Struthers AD, Houston G, MacDonald TM, Lang CC, Donnan PT, George J. Gingles CR, et al. J Hypertens. 2019 Dec;37(12):2481-2489. doi: 10.1097/HJH.0000000000002189. J Hypertens. 2019. PMID: 31268872 Free PMC article. Clinical Trial.
CONCLUSION: Treatment with high-dose allopurinol in normouricemic controlled hypertensive patients and LV hypertrophy is detrimental. ...Cohort selection for future cardiovascular trials with allopurinol is crucial....
CONCLUSION: Treatment with high-dose allopurinol in normouricemic controlled hypertensive patients and LV hypertrophy is detrimental. …
Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.
Ramasamy SN, Korb-Wells CS, Kannangara DR, Smith MW, Wang N, Roberts DM, Graham GG, Williams KM, Day RO. Ramasamy SN, et al. Drug Saf. 2013 Oct;36(10):953-80. doi: 10.1007/s40264-013-0084-0. Drug Saf. 2013. PMID: 23873481 Review.
BACKGROUND: Allopurinol is the primary therapy for the management of chronic gout. Utilization of allopurinol has increased in tandem with the growing prevalence of gout globally. ...Allopurinol was prescribed for approved indications (chronic gout and chemop …
BACKGROUND: Allopurinol is the primary therapy for the management of chronic gout. Utilization of allopurinol has increased in …
Efficacy of the HLA-B(∗)58:01 Screening Test in Preventing Allopurinol-Induced Severe Cutaneous Adverse Reactions in Patients with Chronic Renal Insufficiency-A Prospective Study.
Park HW, Kim DK, Kim SH, Kim S, Chae DW, Yang MS, Oh YK, Lee JP, Jung JW, Shin J, Hwang JH, Kang MG, Kim SM, Kwon SK, Kim HY, Kim MH, Kim SJ, Ryu DR, Cho YJ, Jee YK, Kim SM, Lee EK, Kim JY, Cho HS, Jeong YY, Kim SH, Jun JB, Park JS, Kim GH, Kim S, Jung HY, Lee JM. Park HW, et al. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1271-1276. doi: 10.1016/j.jaip.2018.12.012. Epub 2018 Dec 21. J Allergy Clin Immunol Pract. 2019. PMID: 30580048
By contrast, we identified 38 patients with allopurinol-induced SCARs (0.95%) in the historical control. The difference in the incidence of allopurinol-induced SCARs between the prospective cohort and historical control was statistically significant (0% vs 0.95%, re …
By contrast, we identified 38 patients with allopurinol-induced SCARs (0.95%) in the historical control. The difference in the incide …
Allopurinol-induced toxic epidermal necrolysis featuring almost 60% skin detachment.
Wang F, Ma Z, Wu X, Liu L. Wang F, et al. Medicine (Baltimore). 2019 Jun;98(25):e16078. doi: 10.1097/MD.0000000000016078. Medicine (Baltimore). 2019. PMID: 31232948 Free PMC article.
The patient, being newly diagnosed with gout 10 days ago, received allopurinol at a dose of 250 mg by mouth daily. After 10 days' exposure to allopurinol, the patient manifested with an "influenza-like" prodromal phase (fever of 38°C, throat pains), which was treate …
The patient, being newly diagnosed with gout 10 days ago, received allopurinol at a dose of 250 mg by mouth daily. After 10 days' exp …
Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients.
Cicero AFG, Cosentino ER, Kuwabara M, Degli Esposti D, Borghi C. Cicero AFG, et al. Intern Emerg Med. 2019 Sep;14(6):949-956. doi: 10.1007/s11739-019-02070-y. Epub 2019 Mar 12. Intern Emerg Med. 2019. PMID: 30864092
After a mean follow-up period of 5.1 years, the cumulative cardiovascular survival was 0.96 (95% CI 0.93-0.99) in febuxostat-treated patients and 0.89 (95% CI 0.84-0.93) in those treated with allopurinol. ...Our study results suggest that possibility that febuxostat, a sel …
After a mean follow-up period of 5.1 years, the cumulative cardiovascular survival was 0.96 (95% CI 0.93-0.99) in febuxostat-treated patient …
Bullous cutaneous reactions.
Jira M, Amezyane T. Jira M, et al. Pan Afr Med J. 2018 Nov 16;31:188. doi: 10.11604/pamj.2018.31.188.16608. eCollection 2018. Pan Afr Med J. 2018. PMID: 31065326 Free PMC article. No abstract available.
10,517 results
Jump to page
Feedback